Patient | Antigen | Pre | Post | Follow up 1 | Follow up 2 |
|---|
Her2-I-01
| ICD | - | - | + (150) | + (23) |
| | ECD | - | + (23) | + (114) | + (24) |
Her2-I-02
| ICD | - | + (22) | - | N/A |
| | ECD | - | N/A | - | N/A |
Her2-I-03
| ICD | - | - | - | + (23) |
| | ECD | + (49) | - | - | + (23) |
DC-ICD-MAT-01
| ICD | - | + (18) | N/A | - |
| | ECD | - | - | N/A | - |
DC-ICD-MAT-02
| ICD | N/A | - | - | - |
| | ECD | N/A | - | - | - |
DC-ICD-MAT-03
| ICD | - | N/A | N/A | + (77) |
| | ECD | - | N/A | N/A | + (129) |
FL-DC-MAT-01
| ICD | - | - | - | - |
| | ECD | + (46) | - | - | + (84) |
- A positive ELISpot result is represented by + and the number of spots per 100,000 PBMC in parentheses. A positive (+) result is defined as the number of cells secreting IFNγ in response to HERr2-ICD or ECD that is at least 10 more than the number of cells secreting IFNγ in response to media alone (control cells) and which is statistically greater than the control cells with p < 0.05.
- Each antigen was tested in replicates of 6 for each time point.
- Pre represents ELISpot results prior to vaccination, post represents results during or following the vaccination series, and the follow up timepoints represent up to 5 years following the study.
